Erlotinib News and Research

RSS

Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.

16 Dec 2013

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers say that a drug approved to treat lung cancer substantially shrank tumors in mice that were caused by a rare form of bone cancer called chordoma.

12 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

Investigational c-Met inhibitor shows early promise in NSCLC

A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.

3 Dec 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report.

30 Sep 2013

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

12 Sep 2013

Personalized treatment may be effective in wild type cancers

As a woman in her mid-forties who didn't smoke, Elizabeth Lacasia never expected to be diagnosed with lung cancer. But in 2006, after she developed a persistent and serious cough, a chest X-ray and CT scan revealed several tumors in her lower left lung.

11 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.

6 Sep 2013

Chemotherapy best second-line option for EGFR wild-type NSCLC

Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found.

5 Sep 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.

2 Jul 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Researchers find tumors with ALK rearrangements can harbor additional mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment.

23 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013